Loading color scheme

Celdara Medical announces DRIVEN hub participant company, CoreMap, closed Series A investment of $10.5 Million

Celdara Medical, LLC today announced that DRIVEN Accelerator Hub Participant Company, CoreMap, has closed a Series A investment of $10.5 M led by Qure Ventures.

The round included existing investors such as Ronny Ginor, MD of Fifth Focus/HRMG Investments and Orbimed Venture Partners, and a diverse group of new strategic, corporate, and financial partners. Of the eight companies that have participated in the NIH-funded DRIVEN Accelerator Hub since its establishment in late 2018, this represents the fourth investment round raised. These investments are in addition to numerous NIH grants awarded and commercial sublicenses executed.

Jake Reder, PhD, Celdara’s CEO and Principal Investigator of the DRIVEN Accelerator Hub stated, “We are extremely excited by CoreMap’s ongoing success. Their technology has enormous potential to provide significant benefits for patients with Atrial Fibrillation – a patient population currently underserved by today’s technologies. The CoreMap technology aims to enable curative treatment – an option currently unavailable to 99% of U.S. patients. This is a truly transformational technology.”

CoreMap is a privately funded company founded in 2016 and based in Vermont. They have developed a new technology to improve diagnosis for the 33 million patients with Atrial Fibrillation (AF). At the heart of CoreMap’s technology is a patented electrode pair design in a high-density array configuration combined with algorithm driven mapping and visualization software that will enable electrophysiologists to make more informed therapeutic decisions and improve patient outcomes. The CoreMap technology was invented by Peter Spector, MD a practicing clinical electrophysiologist and now Chair of the Scientific and Clinical Advisory Board. Cofounded by CEO & President Sarah Kalil and advised by a team of leading clinicians and developers, CoreMap is enabled to deliver a superior solution for AF patients. Learn more about the science and the company here.

“The DRIVEN Accelerator Hub was a great experience for CoreMap.  This type of networking and fundraising support is invaluable for an early-stage innovation company like ours,” said Sarah Kalil, CoreMap’s Co–Founder and CEO. 

CoreMap joins the growing list of DRIVEN alums accelerating their companies toward clinical and commercial success. 

 

Changing lives through

innovation

learn more

SNAPSHOT

Building a track record of success

25
+
active product programs
150
M+
invested in innovation & product development
5
Research Sites
4
startups
12
revenue- driving agreements

What We Do

Virtici provides the leadership, space and funding support to transform innovations into products...

VALUE CREATION

  • 1 Select

  • 2 Innovate

  • 3 Develop

learn more

Virtici leadership brings decades of experience  
that intersect innovation and product development.

Meet the team

Virtici Ecosystem

Together we increase our reach and capital, resulting in enhanced innovation, cost-efficient product development, and more valuable medical products for patients.

 

Areas Of Innovation

Virtici is actively seeking the most innovative product and
platform concepts in the following disease areas.

  • Oncology

  • Microbiome

  • Neurology

  • Autoimmunity

  • Inflammation

  • Infectious Disease


learn more

 

The ASCEND Hub is a Regional Technology Accelerator Hub for the seven Western States: Alaska, Hawaii, Idaho, Montana, Nevada, New Mexico, and Wyoming. The NIH funded program empowers innovators to accelerate biomedical commercialization through entrepreneurial education, mentorship, and technology development funding.

learn more

Latest News

FDA Clears Rise Therapeutics’ IND Application to Initiate a Phase 1 Clinical Study of Its Novel Oral Immunotherapy for the Treatment of Rheumatoid Arthritis

Rockville, Maryland – Rise Therapeutics, a biotechnology company engaged in developing novel oral immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a rheumatoid arthritis Phase 1 clinical trial for its program candidate, R-2487. This is Rise Therapeutics’ second clinical program developed using synthetic biology and its proprietary oral biologics delivery platform.

Read more

TEDCO Announces Investment into Rise Therapeutics

TEDCO, Maryland’s economic engine for technology companies, announced a recent Seed Funds investment of $200,000 into Rise Therapeutics, a Maryland-based biotechnology company. TEDCO’s Seed Funds invest in early-stage, technology and life sciences companies and provides access to gap financing.

Read more

Funding Announcement for Novel Synthetic Biology Drug Candidate for Acute Respiratory Distress Syndrome, Developed by Rise Therapeutics

Rockville, Maryland - Rise Therapeutics, a biotech company focused on developing novel immunological-directed synthetic biology-based therapeutics, announced today that it has received funding from the National Institutes of Health (NIH) to develop a novel therapeutic for Acute Respiratory Distress Syndrome (ARDS). The funding will support completion of product validation studies and preparation for clinical development for the program.

Read more

Rise Therapeutics Announces FDA Clearance of its IND Application to Initiate a Phase 1 Study of an Oral Immunotherapy for the Treatment of Ulcerative Colitis

Rockville, Maryland, January 31st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.

Read more

Celdara Medical Receives Funding to Develop Broad-Spectrum Antimicrobials for Chronic Lung Infection

Lebanon, NH: The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has awarded Celdara Medical, LLC a Phase I Small Business Innovation Research (SBIR) grant for development of broad-spectrum antimicrobial peptides to combat chronic lung infection in patients with cystic fibrosis (CF).

Read more

Virtici Announces Funding from NIH to Develop a New Treatment for Periodontal Disease

Seattle, Washington - Virtici LLC announced today that the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) award to advance VTC-886, a first-in-class small molecule for the prevention of P. gingivalis infection.

Read more